Introduction {#j_bjmg-2017-0033_s_001}
============

Vitiligo, characterized by milky-white patches on the skin, is an acquired disease of unknown etiology. Histologically speaking, it is caused by a loss of melanocytes \[[@j_bjmg-2017-0033_ref_001]\]. Several theories have been proposed to explain the pathogenesis; these include the autoimmune, the neural and the theory of self-destruction. Most current studies have focused on the genetic etiology, with genes related to the autoimmunity, melanin, and the biological reply process to the oxidative stress, being the most thoroughly investigated \[[@j_bjmg-2017-0033_ref_002], [@j_bjmg-2017-0033_ref_003], [@j_bjmg-2017-0033_ref_004], [@j_bjmg-2017-0033_ref_005], [@j_bjmg-2017-0033_ref_006]\].

With regard to the pathogenic role of oxidative stress in vitiligo, the previous studies were directed toward changes in antioxidant enzyme activity in the blood and tissue. Although some conflicting results were attained, all studies did point to an impact of oxidative stress on vitiligo \[[@j_bjmg-2017-0033_ref_007], [@j_bjmg-2017-0033_ref_008], [@j_bjmg-2017-0033_ref_009], [@j_bjmg-2017-0033_ref_010], [@j_bjmg-2017-0033_ref_011], [@j_bjmg-2017-0033_ref_012]\]. Superoxide dismutase (SOD), one of the primary antioxidant enzymes, was previously studied in relation to vitiligo and to date, three isoforms of SOD have been identified in humans. They are coded by three different genes: copper-zinc SOD (CuZn-SOD), manganese SOD (Mn-SOD), and extracellular SOD. The diversity in their form stems from amino acid alignment, active metal zone and their intra cell location. Copper-zinc SOD, defined as SOD1, is a cytosolic enzyme, Mn-SOD, namely SOD2, exists in the mitochondria; while the expression of the SOD3 enzyme, is limited to only plasma, lymphoid tissue or cerebrospinal liquids \[[@j_bjmg-2017-0033_ref_013], [@j_bjmg-2017-0033_ref_014]\].

Variations of SOD1 have previously been studied in relation to several clinical manifestations including amyo-trophic lateral sclerosis (ALS) and diabetes mellitus (DM) \[[@j_bjmg-2017-0033_ref_015], [@j_bjmg-2017-0033_ref_016], [@j_bjmg-2017-0033_ref_017]\]. However, to the best of our knowledge, no studies considering associations between either gene polymorphism SOD1 35 A/C (rs2234694) or SOD2 A16V (C/T) (rs4880) and vitiligo is currently available in the literature. The aim of this study was to investigate the polymorphisms of the SOD1 and SOD2 and their impact on Turkish vitiligo patients.

Materials and Methods {#j_bjmg-2017-0033_s_002}
=====================

Patients {#j_bjmg-2017-0033_s_002_s_001}
--------

The study included 101 vitiligo patients, with a control group of 99. The diagnosis of vitiligo was based on clinical findings and the Wood lamp examination, while a vitiligo-free family history, and adequate general health, qualified probands for the control group. Types and volumes of vitiligo in relation to the study group are summarized in [Table 1](#j_bjmg-2017-0033_tab_001){ref-type="table"} (focal, segmental, acrofacial, generalized universal and mixed). Other factors, such as disease duration, family history and comorbidities including DM or Hashimoto's thyroiditis were also noted. Written informed consent was obtained from all subjects. The study was approved by the Ethics Committee of Ege University Medical Faculty, Izmir, Turkey.

###### 

Demographic and clinical parameters of vitiligo patients. (Values are presented as mean.)

  Clinical Type   *n*   Gender   Age                                             
  --------------- ----- -------- ----------- ----------- ----------- ----------- ---------------------------
                  *n*   \%       F *n* (%)   M *n* (%)   F *n* (%)   M *n* (%)   
  Focal           46    45.55    25          24.76       22          21.78       35.62; F: 32.16; M: 39.39
  Acrofacial      25    24.75    13          12.87       11          10.89       32.15; F: 31.26; M: 33.42
  Generalized     21    20.79    13          12.87       8           7.92        38.78; F: 41.34; M: 34.62
  Segmental       4     3.96     2           1.98        2           1.98        27.35; F: 27.50; M: 27.20
  Universal       3     2.97     3           2.97        --          --          37.56
  Mixed           2     1.98     2           1.98        --          --          36.15
  Total           101   100.00   58          57.43       43          43.57       

F: females; M: males.

DNA Isolation and Genetic Analyses {#j_bjmg-2017-0033_s_002_s_002}
----------------------------------

Two milliters of peripheral blood were extracted from each participant, collected into EDTA tubes and stored at --20 °C. Genomic DNA was then isolated from the peripheral blood using standard techniques (DNA Isolation Blood Mini Kit; Invitek, Berlin, Germany).

PCR-RFLP Analyses {#j_bjmg-2017-0033_s_002_s_003}
-----------------

For the polymorphism analysis of SOD1 35 A/C and SOD2 A16V (C/T), polymerase chain reaction-restriction fragment length polymorphim (PCR-RFLP) was performed on both occasions. For SOD1 gene 35 A/C polymorphism, PCR was initiated using forward (5′-CTA TCC AGA AAA CAC GGT GGG CC-3′) and reverse (5′-TCT ATA TTC AAT CAA ATG CTA CAA AAC-3′) primers. For *SOD2* gene A16V (C/T) polymorphism, forward (5′-AGC AGG CAG CTG GCG CCG G-3′) and reverse (5′-GCG TTG ATG TGA GGT TCC AG-3′) primers were used. A total volume of 25 μL, containing 50 ng DNA, 2 mM dNTPs, 2 nmol of each related primer, 1.5 mM MgCl2 and 3U Taq polymerase, was used in each polymorphism PCR set up. Each PCR cycle consisted of denaturation at 94 °C for 30 seconds, extension at 72 °C for 30 seconds, and a final extension step of incubation at 72 °C for 7 min. Annealing temperatures were 55 °C and 59.6 °C for 30 seconds for SOD1 35 A/C and SOD2 A16V (C/T) polymorphisms, respectively.

Genotyping of the *SOD1* Gene 35 A/C Polymorphism {#j_bjmg-2017-0033_s_002_s_004}
-------------------------------------------------

The 278 bp PCR products for the *SOD1* gene 35 A/C polymorphism were digested using the restriction enzyme *Hha*I (Fermentas, The Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C for 3 hours with 5U enzymes. The presence of the 35C mutant allele manifested through the appearance of sites of restriction. Following enzyme digestion, products were then cut into two fragments of 207 and 71 bp ([Figure 1](#j_bjmg-2017-0033_fig_001){ref-type="fig"}).

![Gel images of each genotype along with DNA ladder (100 bp plus).](bjmg-20-067-g001){#j_bjmg-2017-0033_fig_001}

Genotyping of the *SOD2* Gene A16V (C/T) Polymorphism {#j_bjmg-2017-0033_s_002_s_005}
-----------------------------------------------------

A 267 bp amplicon of the *SOD2* gene A16V (C/T) polymorphism was digested using *Ngo*MIV (Fermentas) restriction endonuclease, left overnight at 37 °C. Due to the presence of a mutant allele, the 267 bp PCR amplification product digested into fragments of 183 and 84 bp, respectively ([Figure 1](#j_bjmg-2017-0033_fig_001){ref-type="fig"}). All fragments were visualized *via* electrophoresis on 4.0% agarose gel after restriction. Positive and negative controls were used in each genotyping assay.

Sequencing of the PCR Amplified Product {#j_bjmg-2017-0033_s_002_s_006}
---------------------------------------

As a safeguard, Sanger sequencing of the PCR product was used to confirm the presence of the *SOD1* and *SOD2* gene sequences before continuing ([Figure 2](#j_bjmg-2017-0033_fig_002){ref-type="fig"}).

![The sequencing chromatogram of SOD1 35 A/C and SOD2 Ala9Val (C/T) polymorphisms. A) SOD1 35 AA wild type; B) SOD1 35 AC heterozygotes; C) SOD2 Ala9Val TT wild type; D) SOD2 Ala9Val TC heterozygotes; E) SOD2 Ala9Val CC homozygotes.](bjmg-20-067-g002){#j_bjmg-2017-0033_fig_002}

Statistical Analyses {#j_bjmg-2017-0033_s_002_s_007}
--------------------

The SOD1 35 A/C and SOD2 A16V (C/T) polymorphism allele frequencies of Vitiligo patients were compared to those of a control group using the χ^2^ test; the application of statistical program SPSS 9.0. *p* Values of \<0.05 (one-way) were considered to be significant.

Results {#j_bjmg-2017-0033_s_003}
=======

A total of 101 vitiligo patients; 58 women, (57.4%) and 43 men (42.6%) were enrolled in the study. The mean age was 37.4 ± 15.2; range 7-68 years. The control group consisted of 99 healthy volunteers; 50 women (50.5%) and 49 men (49.5%), with a mean age of 36.6 ± 12.6, range 18-69. In terms of age and gender, no statistical difference existed between the groups.

The median duration of vitiligo was 9.0 years (range 1--35 years). A family history of vitiligo was noted in first-degree relatives of 23 patients (22.7%).

With regard to vitiligo type, 46 patients were focal (45.5%), 25 acrofacial (24.7%), 21 generalized (20.7%), four segmental (3.9%), three universal (2.9%) and two patients were classified as mixed (1.9%). Results can be seen in [Table 1](#j_bjmg-2017-0033_tab_001){ref-type="table"}. The comorbidities in vitiligo patients were as follows: Hashimoto's thyroiditis 12 patients (11.8%), DM 11 patients (10.8%), pernicious anemia two patients (1.9%). When considering the distribution of the comor-bidities between the vitiligo and the control group (*p* = 0.431), no statistical difference was revealed. Similarly, when genotypes of SOD1 35 AA and AC were compared between groups ([Table 2](#j_bjmg-2017-0033_tab_002){ref-type="table"}), the distribution rate was considered insignificant. There was no statistical difference for genotype and allele frequency between the groups (*p* = 0.21) ([Table 3](#j_bjmg-2017-0033_tab_003){ref-type="table"}).

###### 

The genotype and allele distribution in the patient and control groups for the SOD1 35 A/C SOD2 Ala-9Val (C/T) polymorphism.

                  Genotype   Patient *n* %   Control *n* %   Total    *p* Value           
  --------------- ---------- --------------- --------------- -------- ----------- ------- --
  SOD1            AA         96              96.05           97       97.98       193     
  CA              5          4.95            2               2.02     7                   
  CC              0          0.00            0               0.00     0           0.277   
  Total           101        100.00          99              100.00   200                 
                                                                                          
  35 A/C          A          197             97.52           196      98.98       393     
  C               5          2.48            2               1.02     7           0.214   
  Total           202        100.00          198             100.00   400                 
                                                                                          
  SOD2            CC         26              25.70           35       35.36       61      
  CT              37         36.60           40              40.40    77          0 047   
  TT              38         37.60           24              24.24    62                  
  Total           101        100.00          99              100.00   200                 
                                                                                          
  Ala9Val (C/T)   T          154             76.24           124      62.63       278     
  C               48         23.76           74              37.37    122         0.460   
  Total           202        100.00          198             100.00   400                 

Patients HWE: 0.0101, *p* = 0.9199; control HWE: 0.0664, *p* = 0.7966 (SOD1).

^b^ Patients HWE: 2.5320, *p* = 0.1116; control HWE: 5.7681, *p* = 0.0163 (SOD2).

###### 

Distributions of SOD1 35 A/C and SOD2 Ala9Val (C/T) polymorphisms in cases and controls and risk of vitiligo.

         Genotype/Allele   OR            95% CI                                                      *p* Value
  ------ ----------------- ------------- ----------------------------------------------------------- -----------
  SOD1   AA                1             --                                                          --
  AC     0.380             0.072-2.005   0.271                                                       
  A      0.688             0.426-1.110   0.281                                                       
  C      --                --            --                                                          
                                                                                                     
  SOD2   CC                                                                                          
  CT     1                 --            --                                                          
  TT     1.750             0.889-3.446   0.105                                                       
  C      2.158             1.044-4.462   0.038[^a^](#j_bjmg-2017-0033_fn_000){ref-type="table-fn"}   
  T      0.792             0.648-0.968   0.022[^a^](#j_bjmg-2017-0033_fn_000){ref-type="table-fn"}   

This is a statistically significant *p* value.

However, when the patient cohort and control group were compared for the presence of the SOD2 Ala9Val (C/T) polymorphism, the distribution of the genotypes \[*p* = 0.047, odds ratio (OR) = 2.075, 95% confidence interval (95% CI) = 1.008-4.272\] was considered significant. The genotype distribution in vitiligo and the control group was as follows: CC 25.7%, CT 36.6%, TT 37.6%; CC 35.3%, CT 40.4%, TT 24.2%) ([Table 2](#j_bjmg-2017-0033_tab_002){ref-type="table"}). In the TT genotype, relative risk for the development of vitiligo was found to have increased 2-fold. The T allelic frequency was determined as 76.2% in the patient cohort, with 62.67% for the control group, while C allelic frequency was 23.8% in the patients compared to 37.4% for the control group. There was no significant difference for allele frequency (*p* = 0.46) ([Table 2](#j_bjmg-2017-0033_tab_002){ref-type="table"}).

More common alleles of both polymorphisms were considered as reference alleles. Logistic regression analysis showed no significant association between SOD1 35 A/C polymorphism (AA *vs*. AC: OR = 0.380, 95% CI: 0.072-2.005, *p* = 0.271) and SOD2 Ala9Val (C/T) polymorphism (CC *vs*. CT: OR = 1.75, 95% CI: 0.889-3.446, *p* = 0.106). However, a significant association between cases and controls in the SOD2 Ala9Val (C/T) polymorphism (CC *vs*. TT: OR = 2.158, 95% CI: 1.044-4.462, *p* = 0.038) ([Table 3](#j_bjmg-2017-0033_tab_003){ref-type="table"}) was seen. Analysis also confirmed that the presence of the T allele of SOD2 Ala9Val (C/T) polymorphism increased the risk of vitiligo significantly (OR = 0.792, 95% CI: 0.648-0.968, *p* = 0.022) ([Table 3](#j_bjmg-2017-0033_tab_003){ref-type="table"}).

Discussion {#j_bjmg-2017-0033_s_004}
==========

The SOD enzymes together with glutathione peroxidase and catalase play a critical role, assuring the cell protection against free radicals. These enzymes contain redox metals in the centers of their catalytic zones that transform superoxide radicals to hydrogen peroxide and oxygen \[[@j_bjmg-2017-0033_ref_014], [@j_bjmg-2017-0033_ref_015], [@j_bjmg-2017-0033_ref_016], [@j_bjmg-2017-0033_ref_017], [@j_bjmg-2017-0033_ref_018]\].

Oxidative stress can trigger a reaction that causes melanocytes destruction. Thus, the lesions of vitiligo may be brought on by psychological stress or physical events. The trauma and stress cause a catecholamine release, which results in vasoconstriction and hypoxia. Following cellular hypoxia and reoxygenation there is an increase in free oxygen radicals and toxic materials. In a study on malondialdehyde (MDA), level, SOD and glutathione peroxidase activity in the tissues of 114 vitiligo patients, Yildirim *et al*. \[[@j_bjmg-2017-0033_ref_010]\] found tissue SOD activity of the patients was significantly higher than the control group. It was considered that the increased SOD activity observed in that study was caused by a reactive increase against excessive superoxide anion production \[[@j_bjmg-2017-0033_ref_010]\].

This is the first study to evaluate the relationship between the SOD1 and SOD2 polymorphisms and vitiligo. In terms of the SOD2 Ala-9Val (C/T), the TT genotype frequency in the patient group was statistically and significantly higher than the control group. We observed a 2-fold relative risk increase for the development of vitiligo in subjects with the TT genotype. Thus, while not conclusive, our results do suggest that the SOD2 polymorphism might play a role in vitiligo.

In the literature, studies of the CuZn-SOD, described as the SOD1 enzyme, found the frequency of the Ala4Val mutation in SOD1 to be significantly higher than other mutations \[[@j_bjmg-2017-0033_ref_005], [@j_bjmg-2017-0033_ref_019], [@j_bjmg-2017-0033_ref_020]\]. In our study, when we compared the distribution of genotype for the SOD1 35 A/C polymorphism, no significant diversity could be determined (*p* = 0.277). Likewise, when we compared groups, focusing on the SOD1 35 A/C polymorphism allele distribution, no significant diversity could be determined either (*p* = 0.214).

The SOD1 enzyme is cytosolic, and the antioxidant reactions occur in the mitochondria. This might explain the similarity of genotype and allele frequencies in both the cohort and control group.

The SOD2 enzyme, also known as Mn-SOD, has been studied more extensively than SOD1 due to the fact it is mitochondrial and inducible. The production of this particular enzyme rises *via* transcription in conjunction with a rise of the superoxide production. Two polymorphic structures have been determined for the *SOD2* gene: Ala-9Val polymorphisms that is the I1e58Thr polymorphism occurring in the 339th nucleotide *via* the transformation of C to T, and the Ala-9Val polymorphism that occurs in the 1183th nucleotide, again *via* the transformation of C to T. The Ile58Thr polymorphism reduces the enzymatic activity. The Ala/Val change occurs in the protein's mitochondrial target series where it causes greater problems than those associated with the enzyme activity during the transfer of enzymes to the mitochondria \[[@j_bjmg-2017-0033_ref_014]\]. Sutton *et al*. \[[@j_bjmg-2017-0033_ref_021]\] showed that the SOD2 alanine amino acid in liver of rats is more active than the valine amino acid. In this study, results have indicated that the increase in TT homozygosity in vitiligo cases causes problems during the transfer of enzymes to the mitochondria. This is followed by a decrease in the SOD2s antioxidant effect.

The Ala-9Val polymorphism has been studied in relation to Parkinson's disease, schizophrenia, urolithiasis, adult-onset obesity, motor neuron disease, non familial idiopathic dilated cardiomyopathy, age-related macular degeneration, non alcoholic fatty liver disease, diabetic neuropathy, various cancers such as breast, prostate, stomach, colon, lung and skin cancer \[[@j_bjmg-2017-0033_ref_022], [@j_bjmg-2017-0033_ref_023], [@j_bjmg-2017-0033_ref_024], [@j_bjmg-2017-0033_ref_025], [@j_bjmg-2017-0033_ref_026], [@j_bjmg-2017-0033_ref_027], [@j_bjmg-2017-0033_ref_028], [@j_bjmg-2017-0033_ref_029]\]. The SOD2 polymorphism, however, has been generally studied in relation to DM and its associated complications \[[@j_bjmg-2017-0033_ref_029], [@j_bjmg-2017-0033_ref_030], [@j_bjmg-2017-0033_ref_031], [@j_bjmg-2017-0033_ref_032]\].

Previous studies have shown that different polymorphisms from various SOD isoforms can be associated with vitiligo. Additionally, there have also been studies evaluating the expression and enzyme activity of SOD isoforms, in both blood and tissue. Many of these studies have produced conflicting outcomes, especially concerning the peripheral blood samples of vitiligo patients.

Picardo *et al*. \[[@j_bjmg-2017-0033_ref_033]\] showed that blood levels of SOD were not significantly different in vitiligo patients, thus indicating that the melanocyte damage seen in vitiligo was not linked to generalized oxidative stress. In contrast, Laddha *et al*. \[[@j_bjmg-2017-0033_ref_034]\] reported that increased activity of SOD2 and SOD3 due to polymorphisms may be genetic risk factors leading to susceptibility and progression of vitiligo. Hence, suggesting that the genetic make-up of an individual may form a basis for the effective treatment of the disease. In the studies related to SOD expression, both vitiliginous and non vitiliginous skin of patients showed a significant increase in the isoforms of SOD \[[@j_bjmg-2017-0033_ref_035], [@j_bjmg-2017-0033_ref_036]\]. Because the same polymorphism could not be determined in all patients, the idea that the antioxidant system, in conjunction with various other pathways, plays a role in the disease's pathogenesis is well supported.

One of the limitations of this study was our inability to exactly measure the enzyme activities of *SOD1* and *SOD2* genes. It would have been useful to highlight the effects of polymorphisms studied, and correlate the genotyping data. Consequently, this study needs to be substantiated by future studies containing larger patient numbers.
